Neofect "Ybrain Selected for Government Dementia Overcoming R&D Project... Developing Early Dementia Diagnosis Technology"

[Asia Economy Reporter Hyunseok Yoo] NeoFact's affiliate Ybrain announced on the 19th that it has been finally selected for a government dementia overcoming research and development project and will develop early diagnosis prediction technology for Alzheimer's dementia.

The Dementia Overcoming Research and Development Project is a joint initiative by the Ministry of Science and ICT and the Ministry of Health and Welfare to develop technologies to overcome dementia. By 2028, a total of 198.7 billion KRW will be invested to support comprehensive research and development on dementia prevention, diagnosis, and treatment.

Alzheimer's disease is a representative dementia disorder accounting for about 70% of dementia cases. Since the cause of onset is unclear and there is no fundamental cure, perfect prevention and treatment are impossible, making early diagnosis crucial to manage and slow progression.

Ybrain plans to carry out the project titled "Development of Early Diagnosis Prediction Technology for Alzheimer's Dementia Based on Multimodal Neural Signals of Mild Cognitive Impairment Patients" through convergent research with Professor Kyungbok Min of Seoul National University College of Medicine, Central Veterans Hospital, and the Veterans Medical Research Institute.

The project aims to develop early diagnosis prediction technology for Alzheimer's dementia by applying machine learning algorithms to multimodal neural signals and clinical information of mild cognitive impairment patients.

A Ybrain official stated, "We will do our best to develop technology that can slow the progression of dementia in patients through early diagnosis," adding, "If the early diagnosis prediction technology to be developed through this project is linked with Ybrain's existing transcranial direct current stimulation (tDCS) treatment, it will enable the world's first integrated dementia diagnosis support and treatment service."

Ybrain is conducting the world's first home treatment phase 3 clinical trial in the dementia digital therapeutics sector. It targets 120 mild dementia patients at seven university hospitals and is expected to be completed by the end of this year. In addition to dementia, clinical trials are underway for various indications such as depression, migraine, bipolar disorder, insomnia, and autoimmune diseases.

This content was produced with the assistance of AI translation services.